Clinical Trial

Serum Neurofilament-light Chain and GFAP Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis

Study acronym: NeurofilMS
Recruiting
View on ClinicalTrials.gov →
Summary
The investigators hypothesize that serum neurofilament-light chain (NfL) levels can provide information about the level of activity and progression of Multiple Sclerosis at different stages and landmarks of the disease. In addition, Glial Fibrillary Acidic Protein (GFAP) has also been identified as another serum biomarker of disability in MS.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2019-06-07; most recent amendment 2024-05-13.
Status change: Not Yet Recruiting → Recruiting 2019-07-17
Trial Details
NCT Number NCT03981003
Lead Sponsor Centre Hospitalier Universitaire de Nīmes
Collaborators: Hospices Civils de Lyon
Conditions Multiple Sclerosis
Enrollment 1,150 participants
Start Date 2019-05-22
Primary Completion 2028-06 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2024-05-14